GRI Bio holds 2026 annual meeting, re-elects two directors
Stockholders approved an increase to the company's equity incentive plan and ratified its auditor at the November 4 virtual meeting.
GRI Bio, Inc. held its 2026 Annual Meeting of Stockholders on November 4, 2026, at 11:00 a.m. Eastern Time, conducted virtually at www.virtualshareholdermeeting.com/GRI2026.1
Of the company's 2,186,115 shares of common stock issued and outstanding and eligible to vote as of the record date of September 22, 2026, a quorum of 926,474 shares, or approximately 42.37% of the eligible shares, was present in person or represented by proxy at the meeting.1
Stockholders elected two Class III director nominees to serve until the 2029 annual meeting. W. Marc Hertz, Ph.D. received 206,059 votes for, 32,542 against, and 3,438 abstentions, while David Szekeres received 204,761 votes for, 35,933 against, and 1,345 abstentions, with 684,435 broker non-votes for each.1
Shareholders also ratified WithumSmith+Brown, PC as the company's independent registered public accounting firm for fiscal year 2026, with 883,489 votes for, 23,019 against, and 19,966 abstentions.1
A proposal to amend and restate the company's 2018 Equity Incentive Plan was approved. The amendment increases the number of shares of common stock reserved for issuance under the plan by 546,529 shares and extends the evergreen provision to January 1, 2036.1 The vote tally showed 136,205 votes for, 102,978 against, and 2,856 abstentions, with 684,435 broker non-votes.1
A fourth proposal allowing for postponement or adjournment of the meeting if needed to solicit additional proxies also passed, with 828,697 votes for, 57,084 against, and 40,693 abstentions.1
The filing was signed by Leanne Kelly, Chief Financial Officer, on behalf of the company on November 4, 2026.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.